1 / 26

Strategic Approach to Proctitis

Joint Hospital Surgical Grand Round June 2004. Strategic Approach to Proctitis. Department of Surgery Pamela Youde Nethersole Eastern Hospital Dr. Dennis Wong. Contents. Classification & differential diagnoses Epidemiology Specific conditions Approach to proctitis Conclusions.

corinthia
Download Presentation

Strategic Approach to Proctitis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Joint Hospital Surgical Grand Round June 2004 Strategic Approach to Proctitis Department of Surgery Pamela Youde Nethersole Eastern Hospital Dr. Dennis Wong

  2. Contents • Classification & differential diagnoses • Epidemiology • Specific conditions • Approach to proctitis • Conclusions

  3. Background • Definition of proctitis: • Inflammation of the mucous membrane of the rectum • Natural history: • Asymptomatic • Self-limiting • Refractory

  4. Background • Presenting symptoms: • PR bleeding 48% • Diarrhoea 21% • PR mucus 6% • Abdominal pain 6% • Symptomatic anaemia 6% • Altered bowel habit 3% • Urgency 3% • Anal discomfort 3% Lam et al. Ann Coll Surg HK 2000; 4: 62-68

  5. ACUTE Acute self-limiting (procto) colitis (ASLC) Infective proctocolitis Bacterial / viral / parasitic STD / non-STD Pseudomembranous colitis Radiation proctitis NSAID proctitis Ischaemic proctitis Solitary rectal ulcer CHRONIC Inflammatory bowel diseases (IBD) Crohn’s disease UC Radiation proctitis Diversion proctitis Classification & Differential Diagnoses

  6. Epidemiology • Common • True incidence unknown • Lack of prospective trials • Asymptomatic cases & inconclusive tissue biopsies • Variability in definition and grading systems

  7. Specific Conditions Radiation proctitis Pseudomembranous colitis Acute self-limiting colitis

  8. Radiation Proctitis • Consequence of use of megavoltage irradiation therapy in pelvic malignancy (prostate, cervix, ovary, uterus & rectum) • 2 – 25% (1 – 2% chronic) Babb RR. Am J Gastroenterol 1996 • Rectum particularly vulnerable • Fixed organ in pelvis • Glandular-type epithelial cells undergo rapid turnover • Radiation therapy factors • Total radiation dose, dose fractionation, mode of delivery, no. of fields • Dose effect is consistent finding in cervical and prostatic cancer Lawton CA et al. Int J Radiat Oncol Biol Phys. 1991; 21: 935-9

  9. Non-surgical Management of Late Radiation Proctitis Denton AS et al. British Journal of Cancer 2002; 87: 134 – 143 • Systemic review • 63 studies (electronic databases & Grey literature) • Anti-inflammatory agents: • First-line agents • Kochhar et al 1991: Oral sulfasalazine + rectal steriods vs rectal sucralfate • Rectal sucralfate superior both clinically & endoscopically • Rougier et al 1992: Betamethasone vs hydrocortisone enemas • No statistically significant difference • Cavcic et al 2000: • Metronidazole showed reduction in rectal bleeding

  10. Sucralfate enemas: • Highly sulphated polyanionic dissacharide • Stimulate epithelial healing and formation of protective barrier • Kochhlar et al 1991: • Strongest evidence for use of sucralfate • Formalin therapy: • Produces local chemical cauterisation • 15 references • Technique and concentration varies – irrigation, direct application, 3.6%, 4% 10% solutions • Beneficial • ~5% serious s/e: anal ulceration, rectal stricture, incontinence, anal pain • Duration of effect: minimum of 3 months

  11. Thermal coagulation therapy: • Coagulation of focal bleeding • YAG laser, Argon plasma coagulation, bipolar and heater probes • Several treatment sessions • All statistically significant • Jensen et al 1997: • Mean of 4 sessions / case Recommendations:  Sucralfate > Anti-inflammatory agents  greater effect with Metronidazole To consider thermal coagulation, if medically unsuccessful

  12. Indications for Surgery 1) Unresponsive to medical therapies 2) Complications: • Massive haemorrhage - Rectovaginal fistula • Perforation - Secondary malignancy • Strictures • Problems with surgery: • High incidence of anastomotic dehiscence • Poor tissue healing • Chronic pelvic sepsis

  13. Pseudomembraneous Colitis • Clostridium difficile – gram-positive anaerobic bacillus • ~ 1% asymptomatic carriers • ~ 1% on antibiotics affected • Antibiotics therapy changes faecal flora (esp broad-spectrum) • Exotoxins(toxin A & B) are cytotoxic • Produces mucosal inflammation and cell damage epithelial necrosis  pseudomembrane (mucin, fibrin, leucocytes & cellular debris)

  14. Mild Diarrhoea  Pseudomembranous Colitis  Fulminant Colitis Toxic Megacolin  Perforation • Dx • Detection of toxin in stool by ELISA • Rx • Stop antibiotics • Resuscitation • Metronidazole (1st line) • Vancomycin (2nd line) • Surgery • 10% relapse due to failure to eradicate / re-infection Bartlett JG. N Eng J Med 2002; 346: 334-339

  15. Acute Self-limiting Colitis (ASLC) • Idiopathic • Difficult to distinguish from IBD • Symptoms • 20 – 40% of UC start as proctitis and spread proximally • Up to 50% of Crohn’s have rectal involvement • Histology Tytgat GNJ et al. Netherlands Journal of Medicine 1990; S37-42 • Histological definition: • Mucosal inflammation in the absence of both increased mucosal gland branching and glandular architecture distortion Dundas SA et al. Histopathology 1997; 37: 60-66

  16. ASLC

  17. Crohn’s UC

  18. Histological criteria for ASLC and IBD Independent variables Surawicz CM et al. Mucosal biopsy diagnosis of colitis: ASLC & CIBD. Gastroenterology 1994

  19. ASLC • Clinical Outcome: • 1/3 completely resolve by observations alone • 1/3improve by observations alone • 1/3 require drug treatment (steroid enema / oral salicylates) • 10% require long-term treatment • 6% develop into IBD Lam TYD et al. Ann Coll Surg HK 2000; 4: 62-68

  20. How should we approach proctitis?

  21. History(travel, drugs, RT, surgery) PR – fissures, fistulae, skin tags Sigmoidoscopy – ?piles, polyp, tumour PROCTITIS -ve Infective Non-infective Radiation proctitis Stool c/st, ova & cyst C difficile toxin Widal’s test Antiamoebic titre ESR, CRP Colonoscopy + random biopsies Small bowel enema? No response Rx +ve IBD ASLC Others Ischaemic Solitary rectal ulcer Diverticulosis Observation Drugs Rx +ve Repeat Bx

  22. Conclusions • Proctitis is common with many different causes • It is important • Debilitating symptoms • Difficult to differentiate from IBD initially • The decisions on the need for further investigation & initial • treatment should be based on history and clinical assessment • Prognosis is generally very good, however, for ASLC • up to 10% may need long-term therapy • up to 6%  IBD

  23. Thank you

More Related